Dual-targeted N-PMIplus@CA nanoplatform for concurrent MDM2 and β-catenin inhibition in p53 wild-type lung adenocarcinoma

Lung adenocarcinoma (LUAD) harboring wild-type p53 remains therapeutically challenging because of the oncogenic MDM2-driven suppression of p53 activity and compensatory activation of Wnt/β-catenin signaling. Here, we report a self-assembled nanoparticle system (N-PMIplus@CA) enabling simultaneous in...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Ni Zhao, Weiming You, Xiaoqiang Zheng, Jin Yan, Peili Wang, Yu Yao, Wangxiao He, Tianya Liu
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2025-10-01
Schriftenreihe:	Materials Today Bio
Schlagworte:	Lung adenocarcinoma (LUAD) p53 wild-type MDM2 inhibition Wnt/β-catenin signaling Dual-targeted nanomedicine
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2590006425007069
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!